Tissue Therapies has a worldwide exclusive license to commercialise VitroGro® through an Intellectual Property License Agreement with Queensland University of Technology.

Invitrogen Corporation (Nasdaq: IVGN) exclusively sells and distributes synthetic VitroGro® protein and cell culture products manufactured to Good Manufacturing Practice (GMP) standard through a world wide exclusive agreement between Tissue Therapies Ltd and Invitrogen Corporation.

Novozymes A/S and Tissue Therapies Ltd have a joint development agreement to develop advanced wound dressing products combining proprietary Novozymes technologies with Tissue Therapies' VitroGro® technology.

Investment Bank Orbit Capital (www.orbitcapital.com.au) is a corporate advisor to Tissue Therapies Ltd, and has been responsible for establishing the company, corporate structuring, capital raising and other commercial advice.